AstraZeneca announces improvements in pCR rate in DESTINY-Breast11 trial

Positive results from the DESTINY-Breast11 Phase III trial showed ENHERTU followed by paclitaxel, trastuzumab and pertuzumab, THP, in the neoadjuvant setting demonstrated a statistically significant and clinically meaningful improvement in the pathologic complete response, pCR, rate. The trial compared ENHERTU followed by THP with dose-dense doxorubicin and cyclophosphamide followed by THPin patients with high-risk, locally advanced HER2-positive early-stage breast cancer. Pathologic complete response is defined as no evidence of invasive cancer cells in the removed breast tissue and lymph nodes following treatment. In DESTINY-Breast11, ENHERTU followed by THP resulted in a pCR rate of 67.3% compared with 56.3% for ddAC-THP, representing a pCR rate improvement of 11.2%. Improvement in pCR rates was observed across both hormone receptor-positive and HR-negative subgroups.